5Y Capital

Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in genetic sequencing technology and diagnostic solutions. Founded in 2016, the company develops a variety of products, including genome extraction kits for stool, blood, saliva, and bacteria. Axbio also provides advanced sequencing systems, disposable biochips, and reagents. The company is focused on creating high-throughput molecular diagnostics through its novel microfluidic Bio-CMOS platform, which supports both low-cost handheld devices for bedside diagnostics and fully automated laboratory instruments. This technology enables applications such as early cancer screening, rapid pathogen detection, and drug development. Currently, Axbio operates in stealth mode as it continues to innovate within the field.

Ailurus Biotechnology is a biocomputer company focused on advancing the field of synthetic biology. The company creates a platform that streamlines biotechnology research and development, enabling the development of biological products to be as efficient and straightforward as software development. Its innovative operating system allocates resources and manages processes, while offering cloud-accessible bio-computation infrastructures. Through these efforts, Ailurus Biotechnology aims to enhance the efficiency of the biotech industry, transforming the way biological research and product development are conducted.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

AliveX is a developer of an AI-driven immunology platform that focuses on biomarker discovery. By integrating artificial intelligence with multi-omics data and computational biology, the company aims to decode the human immune system. This innovative approach supports immunologists, molecular biologists, and clinical experts in addressing significant clinical challenges. Through its platform, AliveX seeks to transform life sciences research and advance the development of diagnostics, paving the way for the next era of target and biomarker research and development.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

AliveX is a developer of an AI-driven immunology platform that focuses on biomarker discovery. By integrating artificial intelligence with multi-omics data and computational biology, the company aims to decode the human immune system. This innovative approach supports immunologists, molecular biologists, and clinical experts in addressing significant clinical challenges. Through its platform, AliveX seeks to transform life sciences research and advance the development of diagnostics, paving the way for the next era of target and biomarker research and development.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

Redesign Science, established in 2017 and headquartered in New York, is a biotechnology company specializing in small molecule drug discovery. It employs a computational chemistry platform to accelerate drug development by simulating protein targets at the atomic level, revealing subtle drug opportunities that traditional methods may miss. The company aims to set a new standard in early-stage drug discovery, leveraging first-principles physics and artificial intelligence to create generative AI for drug discovery, focusing on emerging and challenging targets with high unmet medical needs.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

TaiMei Technology is a digital innovator specializing in the research and development sector of the life sciences industry. The company has created a comprehensive digital platform that facilitates clinical research by offering insights into various stages of drug development, pharmacovigilance, marketing, and market access. By leveraging advanced technologies such as artificial intelligence, big data, cloud computing, and mobile internet, TaiMei provides integrated solutions that support industry stakeholders throughout the entire product life cycle. The platform encompasses a range of functionalities, including clinical data management, medical imaging, trial management, and drug monitoring, all aimed at enhancing clinical research efficiency. Ultimately, TaiMei Technology is focused on building the future infrastructure of the life sciences industry to expedite product launches, improve drug safety, and enhance accessibility for patients and healthcare providers.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.